Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

doi:10.1016/j.jmoldx.2014.12.006

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

The Journal of molecular diagnostics : JMD - 1 May 2015

Cheng Donavan T, Mitchell Talia N, Zehir Ahmet, Shah Ronak H, Benayed Ryma, Syed Aijazuddin, Chandramohan Raghu, Liu Zhen Yu, Won Helen H, Scott Sasinya N, Brannon A Rose, O'Reilly Catherine, Sadowska Justyna, Casanova Jacklyn, Yannes Angela, Hechtman Jaclyn F, Yao Jinjuan, Song Wei, Ross Dara S, Oultache Alifya, Dogan Snjezana, Borsu Laetitia, Hameed Meera, Nafa Khedoudja, Arcila Maria E, Ladanyi Marc, Berger Michael F

Abstract excerpt

The identification of specific genetic alterations as key oncogenic drivers and the development of targeted therapies are together transforming clinical oncology and creating a pressing need for increased breadth and throughput of clinical genotyping. Next-generation sequencing assays allow the efficient and unbiased detection of clinically actionable mutations. To enable precision oncology in patients with solid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to Genotype

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Neoplasms

Share to Paraffin Embedding

Share to Reproducibility of Results

Source

Open in PubMed Open full text

Identifiers

PMID: 25801821
DOI: 10.1016/j.jmoldx.2014.12.006
PMCID: PMC5808190

Genes

IMPACT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.PMID 25801821Read ↗

Validation of a next-generation sequencing assay for clinical molecular oncology.Semantic proximity Read ↗

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.Semantic proximity Read ↗

Clinical actionability enhanced through deep targeted sequencing of solid tumors.Semantic proximity Read ↗

Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.Semantic proximity Read ↗

Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.Semantic proximity Read ↗

Automated next-generation profiling of genomic alterations in human cancers.Semantic proximity Read ↗

Clinical next generation sequencing to identify actionable aberrations in a phase I program.Semantic proximity Read ↗

A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.Semantic proximity Read ↗

Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.Semantic proximity Read ↗

Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.Semantic proximity Read ↗

Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing.Semantic proximity Read ↗

Clinical and Technical Validation of OncoIndx® Assay – A Comprehensive Genome Profiling Assay for Pan-Cancer InvestigationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.